Erectile Dysfunction Drugs: Market Research Report

April 2010 | 391 pages | ID: E70B186AFB3EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Erectile Dysfunction Drugs in US$ Million.

The report provides separate comprehensive analytics for US, Canada, Japan, Europe,and Rest of the World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 26 companies including many key and niche players worldwide such as Abbott Laboratories, Eli Lilly and Company, Inc., F. Hoffmann-La Roche, Inc., GlaxoSmithKline plc, Nexmed, Inc., Pfizer, Inc., Sanofi-aventis SA, Vivus, Inc., and Warner Chilcott Limited.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Market Scenario
Current & Future Analysis
Challenges
Opportunity for Novel Therapies
Competitive Scenario
Major Drugs
Viagra (sildenafil)
Cialis (tadalafil)
Levitra (vardenafil hydrochloride)
Comparative Analysis
Similarities
Differences
Side Effects

2.PRODUCT OVERVIEW

Introduction
Erectile Dysfunction
Pathophysiology
Causes
Symptoms
Diagnosis
Medical Diagnosis
Patient History
Physical Examination
Laboratory Tests
Other Tests
Psychosocial Examination
Clinical Tests
Duplex Ultrasound
Bulbocavernosus Reflex Test
Nocturnal Penile Tumescence
Penile Biothesiometry
Penile Angiogram
Corpus Cavernosometry
Digital Subtraction Angiography (DSA)
Magnetic Resonance Angiography
Treatment
Overview
Psychotherapy
Behavioral Changes
Stop Smoking
Control Cholesterol
Reduction in Fat
Oral Treatment
Drug Therapy
Other Non-Invasive Treatments
Vacuum Constriction Device
Minimal Invasive Therapies
Surgery
Penile Prostheses
Arterial Surgery
Venous Surgery
Latest Advancements in Treatments
Future Medications for Treatment of Erectile Dysfunction
Alprostadil
Apomorphine
Meloncortin Stimulators
Gene Therapy
Unapproved and Controversial Treatments
Naltrexone
Bremelanotide
Melanotan II
hMaxi-K
Enzyte
Prelox
Yohimbe
Natural Remedies
L-Arginine
Ginkgo
Ginseng
Ashwagandha
Cordiceps Sinensis
Horny Goat Weed
Chinese Angelica
Pomegranate Juice

3.RECENT INDUSTRY ACTIVITY

Warner Chilcott Inks Agreement with Dong-A PharmTech
Warner Chilcott Signs Agreement with NexMed
Coloplast Establishes US Headquarters
Vivus Commences Phase-III Trials of Avanafil
Skreem Entertainment Inks Letter of Intent to Purchase EdMed
Eli Lilly Receives FDA Approval for Cialis®
Eli Lilly Partners with Sanofi-Aventis
Deerfield Management Collaborates with Vivus
Eli Lilly Purchases ICOS

4.FOCUS ON SELECT PLAYERS

Abbott Laboratories (US)
Eli Lilly and Company, Inc. (US)
F. Hoffmann-La Roche, Inc. (US)
GlaxoSmithKline plc (UK)
Nexmed, Inc. (US)
Pfizer, Inc. (US)
Sanofi-aventis SA (France)
Vivus, Inc. (US)
Warner Chilcott Limited (US)

5.GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Erectile Dysfunction Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 2. World Historic Review for Erectile Dysfunction Drugs by Geographic Region – US, Canada, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 3. World 13-Year Perspective for Erectile Dysfunction Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
ED Market Witnesses Robust Demand
User Base Expands with Better Understanding of Disease Indications
Lower Market Penetration Offers Growth Opportunities
Lack of Insurance Coverage Affects ED Drug Sales
Strategic Corporate Developments
Select Players
Abbott Laboratories
Eli Lilly and Company, Inc.
F. Hoffmann-La Roche, Inc.
Nexmed, Inc.
Pfizer, Inc.
Vivus, Inc.
Warner Chilcott Limited

B. MARKET ANALYTICS

Table 4. US Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 5. US Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2.CANADA

Market Analysis

Table 6. Canadian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 7. Canadian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

3.JAPAN

Market Analysis

Table 8. Japanese Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 9. Japanese Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

4.EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Market for Erectile Dysfunction Products to Rise
Development of Novel Drugs for ED and Lifestyle Disorders

B. MARKET ANALYTICS

Table 10. European Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 11. European Historic Review for Erectile Dysfunction Drugs by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 12. European 13-Year Perspective for Erectile Dysfunction Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2009 and 2015

4A.FRANCE

A. MARKET ANALYSIS

Current & Future Analysis
Sanofi-Aventis SA – A Major French Player

B. MARKET ANALYTICS

Table 13. French Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 14. French Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

4B.GERMANY

Market Analysis

Table 15. German Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 16. German Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

4C.ITALY

Market Analysis

Table 17. Italian Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 18. Italian Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

4D.UNITED KINGDOM

A. MARKET ANALYSIS

Current & Future Analysis
GlaxoSmithKline plc – A Major UK Player

B. MARKET ANALYTICS

Table 19. UK Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 20. UK Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

4E.REST OF EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Strategic Corporate Development

B. MARKET ANALYTICS

Table 21. Rest of Europe Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 22. Rest of Europe Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

5.REST OF WORLD

Market Analysis

Table 23. Rest of World Recent Past, Current and Future Analysis for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 24. Rest of World Historic Review for Erectile Dysfunction Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 30)
Region/CountryPlayers
The United States
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East